---
title: 'Worldwide disparities in access to treatment and investigations for nephropathic
  cystinosis: a 2023 perspective'
date: '2023-11-17'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37978055/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231118170631&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Over the last decade, access to investigations (namely
  genetics and IL-CL) and to cysteamine have improved in DEing and TrE. However, discrepancies
  remain with DEed: access to delayed released cysteamine is limited, and reimbursement
  is still profoundly insufficient, therefore limiting their current use. A higher
  resolution version of the Graphical abstract is available as Supplementary ...'
disable_comments: true
---
CONCLUSIONS: Over the last decade, access to investigations (namely genetics and IL-CL) and to cysteamine have improved in DEing and TrE. However, discrepancies remain with DEed: access to delayed released cysteamine is limited, and reimbursement is still profoundly insufficient, therefore limiting their current use. A higher resolution version of the Graphical abstract is available as Supplementary ...